vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and SHORE BANCSHARES INC (SHBI). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $59.1M, roughly 1.4× SHORE BANCSHARES INC). On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 11.8%). SHORE BANCSHARES INC produced more free cash flow last quarter ($59.2M vs $6.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Shore Bancshares Inc. is a U.S. regional bank holding company headquartered in Maryland. It offers a full range of retail and commercial banking services, including deposit products, personal and commercial loans, and wealth management solutions, primarily serving local individual customers, small businesses and mid-sized enterprises in its operating regions.
BLLN vs SHBI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $59.1M |
| Net Profit | $5.7M | — |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | 35.2% |
| Net Margin | 6.8% | — |
| Revenue YoY | 117.4% | 11.8% |
| Net Profit YoY | 138.3% | — |
| EPS (diluted) | $0.10 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $59.1M | ||
| Q3 25 | $83.5M | $56.4M | ||
| Q2 25 | — | $56.6M | ||
| Q1 25 | — | $53.0M | ||
| Q4 24 | $45.1M | $52.9M | ||
| Q3 24 | $38.4M | $50.5M | ||
| Q2 24 | — | $50.6M | ||
| Q1 24 | — | $47.7M |
| Q4 25 | — | — | ||
| Q3 25 | $5.7M | $14.3M | ||
| Q2 25 | — | $15.5M | ||
| Q1 25 | — | $13.8M | ||
| Q4 24 | $-11.5M | — | ||
| Q3 24 | $-14.9M | $11.2M | ||
| Q2 24 | — | $11.2M | ||
| Q1 24 | — | $8.2M |
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 57.1% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 35.2% | ||
| Q3 25 | 11.5% | 33.7% | ||
| Q2 25 | — | 36.5% | ||
| Q1 25 | — | 34.4% | ||
| Q4 24 | 17.0% | 34.3% | ||
| Q3 24 | -32.9% | 29.6% | ||
| Q2 24 | — | 29.7% | ||
| Q1 24 | — | 22.2% |
| Q4 25 | — | — | ||
| Q3 25 | 6.8% | 25.5% | ||
| Q2 25 | — | 27.4% | ||
| Q1 25 | — | 26.0% | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | -38.8% | 22.1% | ||
| Q2 24 | — | 22.2% | ||
| Q1 24 | — | 17.2% |
| Q4 25 | — | $0.48 | ||
| Q3 25 | $0.10 | $0.43 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.41 | ||
| Q4 24 | $-1.13 | $0.39 | ||
| Q3 24 | $-1.47 | $0.34 | ||
| Q2 24 | — | $0.34 | ||
| Q1 24 | — | $0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $355.6M |
| Total DebtLower is stronger | $55.0M | $89.1M |
| Stockholders' EquityBook value | $-239.5M | $589.9M |
| Total Assets | $327.5M | $6.3B |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $355.6M | ||
| Q3 25 | $195.2M | $416.5M | ||
| Q2 25 | — | $185.0M | ||
| Q1 25 | — | $389.0M | ||
| Q4 24 | $191.5M | $459.9M | ||
| Q3 24 | — | $183.6M | ||
| Q2 24 | — | $138.9M | ||
| Q1 24 | — | $114.6M |
| Q4 25 | — | $89.1M | ||
| Q3 25 | $55.0M | $74.5M | ||
| Q2 25 | — | $74.2M | ||
| Q1 25 | — | $74.0M | ||
| Q4 24 | $51.5M | $73.7M | ||
| Q3 24 | — | $123.5M | ||
| Q2 24 | — | $122.8M | ||
| Q1 24 | — | $72.6M |
| Q4 25 | — | $589.9M | ||
| Q3 25 | $-239.5M | $577.2M | ||
| Q2 25 | — | $565.2M | ||
| Q1 25 | — | $552.5M | ||
| Q4 24 | $-251.7M | $541.1M | ||
| Q3 24 | $-242.9M | $533.3M | ||
| Q2 24 | — | $522.8M | ||
| Q1 24 | — | $515.2M |
| Q4 25 | — | $6.3B | ||
| Q3 25 | $327.5M | $6.3B | ||
| Q2 25 | — | $6.0B | ||
| Q1 25 | — | $6.2B | ||
| Q4 24 | $302.1M | $6.2B | ||
| Q3 24 | — | $5.9B | ||
| Q2 24 | — | $5.9B | ||
| Q1 24 | — | $5.8B |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.13× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $62.4M |
| Free Cash FlowOCF − Capex | $6.5M | $59.2M |
| FCF MarginFCF / Revenue | 7.7% | 100.2% |
| Capex IntensityCapex / Revenue | 8.8% | 5.4% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $110.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $62.4M | ||
| Q3 25 | $13.8M | $42.5M | ||
| Q2 25 | — | $-8.3M | ||
| Q1 25 | — | $19.8M | ||
| Q4 24 | — | $46.9M | ||
| Q3 24 | — | $9.1M | ||
| Q2 24 | — | $3.0M | ||
| Q1 24 | — | $2.4M |
| Q4 25 | — | $59.2M | ||
| Q3 25 | $6.5M | $41.9M | ||
| Q2 25 | — | $-9.2M | ||
| Q1 25 | — | $18.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $8.4M | ||
| Q2 24 | — | $1.4M | ||
| Q1 24 | — | $614.0K |
| Q4 25 | — | 100.2% | ||
| Q3 25 | 7.7% | 74.3% | ||
| Q2 25 | — | -16.3% | ||
| Q1 25 | — | 35.4% | ||
| Q4 24 | — | 78.8% | ||
| Q3 24 | — | 16.7% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | — | 5.4% | ||
| Q3 25 | 8.8% | 1.0% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 9.9% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | 3.7% |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | 2.96× | ||
| Q2 25 | — | -0.54× | ||
| Q1 25 | — | 1.44× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.81× | ||
| Q2 24 | — | 0.27× | ||
| Q1 24 | — | 0.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
SHBI
Segment breakdown not available.
